What to Do When Your Innovation Portfolio Is Delivering Low ROI but the Board Demands Growth

Your innovation portfolio delivering low ROI is one of the most uncomfortable positions a UK executive can face: the board wants demonstrable growth, the spending line keeps climbing, and yet the promised returns remain stubbornly out of reach. This tension has sharpened as the UK innovation policy cycle shifts, with the UK Research and Innovation (UKRI) strategy for 2026 to 2031 and evolving Innovate UK programmes recasting where public capability and funding will concentrate. Boards are now asking harder questions about whether internal innovation spend is actually converting into value.

This article gives you a practical, operationally focused triage playbook, diagnostics you can run in a week, a decision matrix to decide what to kill or scale, a 90-day reset plan, governance fixes, and a reframed board conversation. The insights, examples and governance heuristics here are framed with input from a Strategos advisor acting in a consulting capacity, not as legal counsel.

Why your innovation portfolio delivering low ROI happens, common symptoms and root causes

Low returns rarely stem from a single failed project. In most cases, your innovation portfolio delivering low ROI is the visible outcome of structural problems in how ideas are identified, funded, governed and progressed. Before you can fix returns, you need to name the pathology precisely. Three symptoms account for the majority of underperforming portfolios in corporates and scale-ups, and each has a distinct root cause that responds to different interventions.

The temptation for many leadership teams is to treat symptoms as isolated failures, cancelling the loudest underperformer while leaving the underlying mechanism untouched. That approach guarantees the problem recurs. Effective innovation portfolio management starts by diagnosing the system, not scapegoating individual bets.

Symptom 1, Too many pilots, low conversion to scale

The classic signature of a low ROI innovation portfolio is a crowded pipeline of pilots that never graduate. Teams celebrate launching experiments but rarely close them, so resources spread thinly across dozens of half-alive initiatives. The pilots vs scale imbalance means capital and talent are consumed by activity that produces learning but no commercial return. When a portfolio carries many pilots and almost none reaching scale, the root cause is usually the absence of a forcing function, no clear conversion threshold, no default expiry date, and no owner accountable for graduating or ending each experiment.

Symptom 2, Weak funnel discipline and poor metrics

When you cannot state your pilot-to-scale conversion rate, your burn per validated experiment, or your average time-in-stage, you are flying blind and without any instruments. Weak funnel discipline lets projects drift between stages without meeting evidence bars, and poor stage gate metrics mean decisions are made on enthusiasm rather than sound reasoning. This is a frequent driver of your innovation portfolio delivering low ROI: money moves forward because stopping feels like admitting failure, not because the data justifies continued investment. Established innovation-management research consistently underlines that disciplined prioritisation, not volume of activity, separates high-return portfolios from the rest.

Symptom 3, Misaligned incentives and governance gaps

Where executive KPIs reward quick wins and certain outcomes, people behave rationally against the wrong target. Misaligned incentives combined with unclear decision rights create governance gaps: nobody owns the kill decision, review cadences are irregular, and stage gates become rubber stamps. The result is a portfolio that expands but does not deliver, because the organisation is optimised to look busy rather than to generate return.

Rapid portfolio diagnostics, what to measure in 7 days

You do not need a three-month review to understand why your innovation portfolio is delivering low ROI. A focused seven-day diagnostic gives the board enough evidence to act. The objective is not perfect data; it is sufficient signal to distinguish which bets are working, which are draining resources, and where reallocation will move returns fastest.

Who should run the diagnostic and what data to pull

Assign a small triage team: a portfolio manager to own the process, a finance partner to validate spend, and a senior sponsor with authority to endorse decisions. Pull project-level spend, stage history, headcount allocation, and any commercial or usage data already captured. Do not commission new data collection at this stage, work with what exists so the diagnostic stays fast.

Key metrics to compute immediately

Compute a compact set of metrics that expose the mechanics of a low ROI innovation portfolio:

• Pilot-to-scale conversion rate. Percentage of pilots that graduated to scaled deployment over the last 12–24 months.
• Burn per validated experiment. Total spend divided by the number of experiments that produced a clear, decision-grade result.
• Expected NPV bands. A rough high, base and low value estimate for each live initiative, used to rank rather than to forecast precisely.
• Time-in-stage. Average days each project has spent in its current stage, flagging anything stalled well beyond norm.
• Experiment velocity. Number of decision-grade experiments completed per quarter, revealing whether the team is learning or merely occupied.
• Resource utilisation. Share of innovation headcount committed to initiatives with weak evidence.
• Portfolio distribution. Share of resource allocation across core, adjacent and transformational initiatives.

Quick stakeholder interviews

Run short, structured interviews with project leads and key sponsors, around twenty minutes each, three questions in scope: what evidence supports continuation, which critical assumptions still need to be validated, and will it take to progress to the next stage in your funnel. Keep out of scope any relitigating of past decisions or attribution of blame. The interviews surface tacit knowledge the numbers miss and build the buy-in you will need for the harder triage calls.

The triage decision matrix, kill, hold, pivot, or double-down

Once diagnostics are complete, innovation portfolio triage becomes a disciplined sorting exercise. Score each initiative on two axes, strength of evidence and strategic value, then apply consistent thresholds so decisions are defensible to the board and to the teams affected. The point is to replace debate with a scorecard the whole leadership team has agreed in advance.

Kill rules and safe decommissioning

Kill an initiative when the evidence is clearly negative against its core assumption, not merely unproven. Distinguish sharply between a bet that has failed a decisive test and one that simply has not yet been tested. Decommission safely: capture the learning in a short written record, redeploy people promptly, and communicate the decision as a portfolio choice rather than a personal failure. Fast, humane kills release the capital that fixes your innovation portfolio delivering low ROI.

Pivot and reuse learnings

Some initiatives are aimed at the wrong market or built on the wrong model but sit on valuable capability. Pivot when the underlying asset or insight is strong but the current thesis is weak. Reuse the technology, data or customer relationship against a better-defined opportunity, and reset the stage gate so the pivoted bet must earn its next tranche of funding like any new experiment.

Criteria to double down and reallocate budget

Double down where evidence is strong, strategic fit is high, and additional capital demonstrably accelerates a proven path to scale. The discipline to reallocate innovation resources toward these winners, funded largely by the kills, is what converts a stagnant portfolio into one that grows. Concentrate rather than sprinkle: a small number of well-resourced bets typically outperform a broad field of underfunded ones.

The 90-day reset playbook, week-by-week plan

A 90 day innovation plan gives the board something concrete: a milestone-based reset with named owners and outputs at each stage. The structure below moves from evidence to action to sustained governance, so that within a single quarter you can show credible progress on your innovation portfolio delivering low ROI.

Weeks 1–2, Diagnostic closure and immediate kills

Complete the seven-day diagnostic, run the triage matrix, and execute the clear kills. Publish the scorecard internally so decisions are transparent. Redeploy freed headcount into a small holding pool ready for reallocation. The primary output for the board is a one-page summary showing what was stopped, why, and the capital and capacity released.

Weeks 3–6, Reallocation and accelerated experiments

Direct the freed resources toward the double-down candidates and the pivots that need a decisive test. Design tightly scoped experiments with pre-agreed success criteria, so that within weeks you know whether each bet is earning its next tranche. Establish a weekly portfolio stand-up to remove blockers quickly and maintain experiment velocity. The output is a reallocated resourcing plan and a set of running experiments with defined evidence bars, the operational heart of any effort to reallocate innovation resources without losing momentum.

Weeks 7–12, Scaling path and governance changes

By now the accelerated experiments are producing signal. Move validated bets onto a scaling path with clear commercial milestones and dedicated resource. Simultaneously, embed the governance fixes that stop the portfolio drifting back, redesigned stage gates, a fixed review cadence, and adjusted decision rights. The output is a scaling roadmap for the winners and a governance charter that survives beyond the reset.

Measurement cadence and first 90-day board report

Set a monthly portfolio review and a quarterly board update as the permanent rhythm. The first 90-day board report should show the before-and-after picture: conversion improvement, capital reallocated, experiments completed, and the revised KPI dashboard. This is the evidence that reverses the narrative of your innovation portfolio delivering low ROI.

Governance fixes that restore momentum

Triage releases immediate value, but governance keeps it. Without structural change the same symptoms return within a year. The fixes that Strategos advisory engagements consistently prioritise concentrate on three levers: the metrics at each gate, the incentives on executives, and the protocol for moving money between bets.

Stage-gate redesign: right metrics at each gate

Redesign stage gates so each one asks for the evidence appropriate to that stage. Early gates should test problem and demand; middle gates should test the feasibility and unit economics; late gates should test scalability. Attach stage gate metrics that predict progression rather than merely record activity, and make passing a gate genuinely difficult. A gate that everything passes is not governance, it is innovation theatre.

Accountability and incentives: aligning exec KPIs with portfolio outcomes

Rewire executive KPIs so they reward validated outcomes and portfolio ROI, not the number of launches. When leaders are measured on conversion, disciplined killing, and value created rather than pipeline volume, behaviour changes fast. Assign explicit decision rights for kill, pivot and scale calls, so accountability is never diffuse.

Resource reallocation protocol

Establish a standing protocol to reallocate innovation resources at each review, rather than treating budget as fixed for the year. Winners should be able to draw additional capital quickly; underperformers should release it just as fast. A living portfolio budget, revisited monthly, is one of the single most effective structural defences against your innovation portfolio delivering low ROI.

Reframing the board conversation, sample slide deck and narrative

Boards do not want a longer list of projects; they want evidence that innovation spend is managed like an investment portfolio. Reframing board reporting innovation means moving from anecdote to a concise, repeatable narrative supported by a single dashboard. A tight six-slide structure works for most quarterly updates:

1. Portfolio at a glance. Total spend, number of active bets by stage, headline conversion rate.
2. What we stopped and why. Kills executed, capital and capacity released.
3. Where we are investing. The double-down bets and the evidence behind them.
4. Pivots in flight. Reused assets and the revised theses under test.
5. KPI dashboard. Trend lines on conversion, burn per validated experiment, time-in-stage.
6. Ask and outlook. Decisions needed and expected value trajectory.

Three narratives that boards want to hear

Frame the story in one of three ways depending on your position. The risk-managed growth narrative shows how disciplined killing funds concentrated bets, reducing exposure while raising expected return. The portfolio pivot narrative explains how existing capability is being redirected to better opportunities. The funding match narrative connects your roadmap to available public support, showing how UK funding windows can extend internal capital. Each narrative reframes your innovation portfolio delivering low ROI as a managed transition rather than a crisis.

One-page innovation KPI dashboard

Distil the portfolio to a single page the board can read in two minutes: overall portfolio progress, pilot-to-scale conversion, burn per validated experiment, average time-in-stage, experiment velocity, capital reallocated this quarter, and expected NPV of the top bets. Consistency matters more than sophistication, the same six numbers, quarter after quarter, let the board see the trend and hold the portfolio accountable.

UK policy and funding context, what boards must know

Portfolio prioritisation cannot be decided in isolation from the UK funding environment. The UK Research and Innovation strategy for 2026 to 2031 signals where public capability and priority funding will concentrate, and the UK Innovation Strategy sets the broader policy objectives corporates are often expected to align with. Innovate UK’s business growth and support programmes offer practical routes to co-fund and accelerate specific bets, and their funding competitions have real timing implications. Independent benchmarking, such as the University of Cambridge UK Innovation Report and the OECD’s science, technology and innovation indicators, can help boards judge whether their priorities are competitive, while Office for National Statistics research and development expenditure data grounds any internal comparison against national trends.

The practical takeaway for triage: where a pivot or double-down bet aligns with a priority area and an open funding window, its case strengthens because external capital can supplement internal spend. Sequence your reallocation decisions to catch these windows rather than missing them by a quarter. Always confirm eligibility, deadlines and terms directly with the relevant funding body, as competitions and priorities change frequently.

Examples and short case studies

In one Strategos advisory engagement with a manufacturing client, a portfolio of eleven live pilots was carrying just one path toward commercialisation. Applying the triage matrix, the team killed six pilots within two weeks, pivoted two onto adjacent markets, and concentrated the freed budget on the two strongest bets. Within 90 days, conversion signal on the double-down initiatives had improved sharply and burn per validated experiment fell substantially.

In a corporate innovation unit, the core problem was governance rather than idea quality. Executive KPIs rewarded launches, so nothing was ever stopped. Reweighting KPIs toward validated outcomes and installing a monthly reallocation protocol reversed the pattern: within a quarter the unit was concentrating resources on fewer, better-evidenced bets and reporting a credible growth narrative to its board, a direct answer to the problem of an innovation portfolio delivering low ROI.

Quick tools and templates

To operationalise this playbook, use the triage scorecard, the 90-day plan checklist, and the board slide template. These assets turn the framework into a repeatable process your portfolio team can run each quarter. Request a practical guide to innovation portfolio management via the advisor profile linked below.

Conclusion and next steps

Your innovation portfolio delivering low ROI doesn’t have to be a permanent condition, it is a solvable, largely structural problem. Run the seven-day diagnostic, apply the triage matrix to decide what to kill, hold, pivot or double down, execute the 90-day reset, and lock in the governance fixes that stop the pattern recurring. Align your reallocation with UK funding windows to stretch internal capital, and reframe the board conversation around a concise KPI dashboard and a clear growth narrative. Executed with discipline, this sequence turns a stagnant portfolio into one that concentrates on winners and demonstrably grows. To move from diagnosis to execution, you can request the triage templates and advisory support via the Strategos advisor profile.

Sources

1. UK Research and Innovation, Strategy 2026 to 2031
2. UK Government, UK Innovation Strategy
3. Innovate UK, Business Growth
4. Centre for Industrial Innovation Policy, University of Cambridge, UK Innovation Report 2026
5. Office for National Statistics, Research and development expenditure
6. OECD, Science, Technology and Innovation